Project Grant R01CA315634
Award Date 7/9/26
Completion Date 6/30/31
Dollars Obligated $646K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Ann Arbor, MI 48109, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the Regents of the University of Michigan a $544,868 Project Grant on June 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate the role of the SLC13A3 transporter in tumor resistance to immunotherapy. The research aims to elucidate mechanisms by which the metabolite itaconate—imported via SLC13A3—suppresses Major Histocompatibility Complex Class I (MHC-I) expression in tumor cells, thereby...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded the Regents of the University of Michigan $646,949 under the Cancer Biology Research program (CFDA 93.396) on July 9, 2026, for research into ADAR1 (Adenosine Deaminase Acting on RNA 1) post-translational modifications in cancer immunity and immunotherapy. The five-year project, scheduled for completion by June 30, 2031, will investigate how ADAR1—an RNA editing enzyme that converts adenosine to inosine in...
- Federal Grant Award Summary The University of Michigan received a $669,278 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) for the period June 1, 2026 through May 31, 2031. This research initiative develops engineered, tumor-tropic Escherichia coli bacteria displaying membrane-bound immune cytokines—specifically decoy-resistant interleukin-18 (DR-18)—to enhance localized anti-tumor immune activation while minimizing systemic...
- Federal Project Grant Award Summary The National Cancer Institute (NCI), under the Cancer Biology Research program (CFDA 93.396), awarded $660,808 to the Regents of the University of Michigan to investigate the durability and function of tissue-resident memory T cells (TRM) in melanoma immunotherapy response. The five-year project, awarded April 7, 2026, and concluding March 31, 2031, will deliver fundamental cancer immunology research examining how TRM cells established at primary melanoma...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $400,614 through its Cancer Biology Research program (CFDA 93.396) to the University of Michigan, effective July 6, 2026, with a completion date of June 30, 2031. This Project Grant supports fundamental research investigating uridine metabolism as a therapeutic target in pancreatic ductal adenocarcinoma (PDA). The research addresses a critical gap in cancer treatment, as PDA is projected to become the second...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the Regents of the University of Michigan a $571,735 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective July 1, 2026, through June 30, 2031. This research grant supports fundamental investigation into mechanisms by which collagen extracellular matrix (ECM) disruption potentiates anti-glioma immune responses. Glioblastomas represent the most aggressive primary brain tumors with median survival...
- Federal Project Grant Award Summary The National Cancer Institute (NCI), under the Cancer Research Manpower program (CFDA 93.398), awarded the Regents of the University of Michigan $152,586 on December 12, 2025, for cancer research training and workforce development. The award, with a completion date of June 16, 2028, supports biomedical training opportunities designed to prepare individuals for careers in cancer research aligned with the National Cancer Program. The project, titled "MS4A...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $136,412 to the Regents of the University of Michigan, effective August 1, 2025 through July 31, 2027, under the Cancer Research Manpower program (CFDA 93.398). This award funds research aimed at defining and interrupting metabolic crosstalk in the glioblastoma microenvironment. The research builds upon preliminary findings demonstrating that glioblastoma (GBM) tumors acquire nutrients through...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Sloan-Kettering Institute for Cancer Research a Project Grant of $671,252 under the Cancer Biology Research program (CFDA 93.396), effective July 1, 2026, through June 30, 2031. This five-year research initiative investigates the mechanisms by which CD4 T cells and dendritic cells (DC) work in concert with CD8 T cells to enhance anti-tumor immunity. Specifically, the research focuses on understanding how...
- Federal Grant Award Summary The National Cancer Institute awarded the Regents of the University of Michigan a Project Grant totaling $646,920 under the Cancer Treatment Research program (CFDA 93.395) on March 11, 2026, with completion targeted for February 28, 2031. The research project, titled "Novel Multi-Targeted Strategies Targeting T-Cell Lymphomas and Their Microenvironment," aims to develop and evaluate improved therapeutic approaches for T-cell lymphomas (TCL), which...